Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes: A prospective cohort study
Abstract Background and Aims The goal of the present study was to systematically evaluate the effect of a booster vaccination with the BNT162b2 messenger RNA (mRNA; Pfizer‐BioNTech®) vaccine on maximum oxygen uptake (VO2max), potential signs of (peri)myocarditis, and sports participation. Methods Re...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.929 |
| _version_ | 1797772313561661440 |
|---|---|
| author | Hielko Miljoen Youri Bekhuis Johan Roeykens Karim Taha Rudi Frankinouille Matthijs Michielsen Caroline M. Van de Heyning Véronique Cornelissen Kasper Favere Sander Eens Jan Gielen Kaatje Goetschalckx Hein Heidbuchel Guido Claessen Covivax Study Group |
| author_facet | Hielko Miljoen Youri Bekhuis Johan Roeykens Karim Taha Rudi Frankinouille Matthijs Michielsen Caroline M. Van de Heyning Véronique Cornelissen Kasper Favere Sander Eens Jan Gielen Kaatje Goetschalckx Hein Heidbuchel Guido Claessen Covivax Study Group |
| author_sort | Hielko Miljoen |
| collection | DOAJ |
| description | Abstract Background and Aims The goal of the present study was to systematically evaluate the effect of a booster vaccination with the BNT162b2 messenger RNA (mRNA; Pfizer‐BioNTech®) vaccine on maximum oxygen uptake (VO2max), potential signs of (peri)myocarditis, and sports participation. Methods Recreational athletes who were scheduled to undergo booster vaccination were evaluated with transthoracic echocardiography, serum measurements of high‐sensitivity C‐reactive protein(hsCRP) and high‐sensitivity troponin I, and a bicycle cardiopulmonary exercise test (CPET) with serum lactate evaluation before the booster vaccine administration. Seven days postvaccination the test battery was repeated. Additionally, the subjects were asked to fill in a questionnaire on side effects and a subjective evaluation of their relative training volume and intensity as compared to the weeks before vaccination. Results A group of 42 analysed athletes showed a statistically significant 2.7% decrease in VO2max after vaccination (mean standard error of mean pre: 48.6 (1.4) ml/kg/min; post: 47.3 (1.4) ml/kg/min; p = 0.004). A potentially clinically relevant decrease of 8.6% or more occurred in 8 (19%) athletes. Other CPET parameters and lactate curves were comparable. We found no serological or echocardiographic evidence of (peri)myocarditis. A slight but significant increase in hsCRP was noted 1 week after vaccination. Side effects were mild and sports participation was generally unchanged or mildly decreased after vaccination. Conclusion In our population of recreational endurance athletes, booster vaccination with the BNT162b2 mRNA vaccine resulted in a statistically significant decrease in VO2max 7 days after vaccination. The clinical impact hereof needs to be further determined. No major adverse events were observed. |
| first_indexed | 2024-03-12T21:50:15Z |
| format | Article |
| id | doaj.art-812f770ad56348648d3547ca5bb5a08b |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-03-12T21:50:15Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-812f770ad56348648d3547ca5bb5a08b2023-07-26T04:31:46ZengWileyHealth Science Reports2398-88352022-11-0156n/an/a10.1002/hsr2.929Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes: A prospective cohort studyHielko Miljoen0Youri Bekhuis1Johan Roeykens2Karim Taha3Rudi Frankinouille4Matthijs Michielsen5Caroline M. Van de Heyning6Véronique Cornelissen7Kasper Favere8Sander Eens9Jan Gielen10Kaatje Goetschalckx11Hein Heidbuchel12Guido Claessen13Covivax Study GroupDepartment of Cardiology Antwerp University Hospital Antwerp BelgiumDepartment of Cardiovascular Sciences Cardiology, KU Leuven Leuven BelgiumDepartment of Cardiology Antwerp University Hospital Antwerp BelgiumDepartment of Cardiovascular Sciences Cardiology, KU Leuven Leuven BelgiumDepartment of Cardiology Antwerp University Hospital Antwerp BelgiumDepartment of Rehabilitation Sciences, Group Rehabilitation in Internal Disorders KU Leuven Leuven BelgiumDepartment of Cardiology Antwerp University Hospital Antwerp BelgiumDepartment of Rehabilitation Sciences, Group Rehabilitation in Internal Disorders KU Leuven Leuven BelgiumDepartment of Medicine and Health Sciences University of Antwerp Antwerp BelgiumDepartment of Medicine and Health Sciences University of Antwerp Antwerp BelgiumDepartment of Medicine and Health Sciences University of Antwerp Antwerp BelgiumDepartment of Cardiovascular Diseases University Hospitals Leuven Leuven BelgiumDepartment of Cardiology Antwerp University Hospital Antwerp BelgiumDepartment of Cardiovascular Sciences Cardiology, KU Leuven Leuven BelgiumAbstract Background and Aims The goal of the present study was to systematically evaluate the effect of a booster vaccination with the BNT162b2 messenger RNA (mRNA; Pfizer‐BioNTech®) vaccine on maximum oxygen uptake (VO2max), potential signs of (peri)myocarditis, and sports participation. Methods Recreational athletes who were scheduled to undergo booster vaccination were evaluated with transthoracic echocardiography, serum measurements of high‐sensitivity C‐reactive protein(hsCRP) and high‐sensitivity troponin I, and a bicycle cardiopulmonary exercise test (CPET) with serum lactate evaluation before the booster vaccine administration. Seven days postvaccination the test battery was repeated. Additionally, the subjects were asked to fill in a questionnaire on side effects and a subjective evaluation of their relative training volume and intensity as compared to the weeks before vaccination. Results A group of 42 analysed athletes showed a statistically significant 2.7% decrease in VO2max after vaccination (mean standard error of mean pre: 48.6 (1.4) ml/kg/min; post: 47.3 (1.4) ml/kg/min; p = 0.004). A potentially clinically relevant decrease of 8.6% or more occurred in 8 (19%) athletes. Other CPET parameters and lactate curves were comparable. We found no serological or echocardiographic evidence of (peri)myocarditis. A slight but significant increase in hsCRP was noted 1 week after vaccination. Side effects were mild and sports participation was generally unchanged or mildly decreased after vaccination. Conclusion In our population of recreational endurance athletes, booster vaccination with the BNT162b2 mRNA vaccine resulted in a statistically significant decrease in VO2max 7 days after vaccination. The clinical impact hereof needs to be further determined. No major adverse events were observed.https://doi.org/10.1002/hsr2.929athleteCOVID‐19SARS‐CoV‐2vaccinationVO2max |
| spellingShingle | Hielko Miljoen Youri Bekhuis Johan Roeykens Karim Taha Rudi Frankinouille Matthijs Michielsen Caroline M. Van de Heyning Véronique Cornelissen Kasper Favere Sander Eens Jan Gielen Kaatje Goetschalckx Hein Heidbuchel Guido Claessen Covivax Study Group Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes: A prospective cohort study Health Science Reports athlete COVID‐19 SARS‐CoV‐2 vaccination VO2max |
| title | Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes: A prospective cohort study |
| title_full | Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes: A prospective cohort study |
| title_fullStr | Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes: A prospective cohort study |
| title_full_unstemmed | Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes: A prospective cohort study |
| title_short | Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes: A prospective cohort study |
| title_sort | effect of bnt162b2 mrna booster vaccination on vo2max in recreational athletes a prospective cohort study |
| topic | athlete COVID‐19 SARS‐CoV‐2 vaccination VO2max |
| url | https://doi.org/10.1002/hsr2.929 |
| work_keys_str_mv | AT hielkomiljoen effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT youribekhuis effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT johanroeykens effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT karimtaha effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT rudifrankinouille effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT matthijsmichielsen effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT carolinemvandeheyning effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT veroniquecornelissen effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT kasperfavere effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT sandereens effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT jangielen effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT kaatjegoetschalckx effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT heinheidbuchel effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT guidoclaessen effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy AT covivaxstudygroup effectofbnt162b2mrnaboostervaccinationonvo2maxinrecreationalathletesaprospectivecohortstudy |